COMMUNIQUÉS West-GlobeNewswire

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
25/03/2026
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior [...]
Catalyst MedTech Establishes Full Access Neurology Solution as the Industry Standard for Brain PET Implementation in the U.S.
25/03/2026
Full Access Neurology is a proven, end-to-end optimized Brain PET clinical solution—built for real-world implementation PITTSBURGH, March 25, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear [...]
CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier
25/03/2026
DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés sur sa technologie [...]
Financière de Tubize - Convocation des actionnaires à l’Assemblée Générale Ordinaire du 24 avril 2026
25/03/2026
Convocation des actionnaires à l’Assemblée Générale Ordinaire du 24 avril 2026 Les actionnaires sont invités à prendre part à l’assemblée générale ordinaire qui se tiendra le 24 avril 2026 à 11 heures à 1070 Bruxelles ( [...]
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
25/03/2026
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin [...]
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
25/03/2026
SPRING, Texas, March 25, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature , of [...]
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
25/03/2026
Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has Entered into a Definitive [...]
Financière de Tubize - Convening of the ordinary general meetings of shareholders of April 24, 2026
25/03/2026
Convening of the Ordinary Meeting of shareholders of 24 April 2026 The shareholders are invited to attend the ordinary general meeting, which will take place on Friday 24th of April 2026 at 11:00AM at 1070 Brussels ( [...]
InhaleH₂ Earns Canadian SR&ED Recognition for Breakthrough in Hydrogen Therapy Delivery
25/03/2026
SNOQUALMIE, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- InhaleH₂ , a precision hydrogen inhalation technology developed by Alex Tarnava , inventor of the open-cup hydrogen water tablets, and well-known H 2 researcher Dr. [...]
CROSSJECT appoints Lionel Seltz as Chief Financial Officer
25/03/2026
DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto- [...]
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
25/03/2026
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
SafeSpace Global to Attend ISC West 2026 to Strengthen Industry Relationships and Expand Strategic Pipeline
25/03/2026
Knoxville, TN., March 25, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corp. (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions, dedicated to safety innovation [...]
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has completed its previously announced exchange offer to each holder of [...]
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
25/03/2026
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 [...]
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026
25/03/2026
VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual acuity (BCVA) and Virtual Reality Visual Test (VRVT), sustained through six- [...]
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
25/03/2026
BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of [...]
CDT Equity Inc. Announces Reverse Stock Split
25/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
VIVUS Reinforces QSIVA®’s Clinical Efficacy and Safety in Obesity Management
25/03/2026
— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a [...]
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
25/03/2026
FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the [...]

Pages